Skip to main content

Table 1 Mammary tumor totals in rapid and slow acetylator congenic rats administered MNU or DMBA

From: Congenic rats with higher arylamine N-acetyltransferase 2 activity exhibit greater carcinogen-induced mammary tumor susceptibility independent of carcinogen metabolism

Treatment Protocol

Acetylator phenotype

Rats treated and necropsied

Rats with tumors (%)a

Total tumors

Total tumors per ratb,c

Total tumors per rat in tumor- bearing ratsc

MNU 3 weeks

Rapid

42

28 (66.7%)

42

1.00 ± 0.17

1.50 ± 0.20

MNU 3 weeks

Slow

34

18 (52.9%)

23

0.67 ± 0.12

1.28 ± 0.11

MNU 8 weeks

Rapid

24

10 (41.6%)*

12

0.50 ± 0.14*

1.20 ± 0.20

MNU 8 weeks

Slow

33

5 (15.2%)*

8

0.24 ± 0.12*

1.60 ± 0.24

DMBA 8 weeks

Rapid

25

19 (76.0%)*

30

1.20 ± 0.16**

1.58 ± 0.12

DMBA 8 weeks

Slow

30

13 (43.3%)*

17

0.57 ± 0.14**

1.31 ± 0.17

  1. aTumor incidence
  2. bTumor multiplicity
  3. cMean ± SEM. Total mammary tumors differed significantly *(p < 0.05) ** (p < 0.01) between rapid and slow acetylator rats